TMCnet News
Research and Markets: CVT-301 (Parkinson's Disease) by Civitas Therapeutics- Forecast and Market Analysis to 2022DUBLIN --(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/vltc4s/cvt301) has announced the addition of the "CVT-301 (Parkinson's Disease) - Forecast and Market Analysis to 2022" report to their offering. CVT-301 has been developed by Civitas Therapeutics as the company's leading candidate for the treatment of OFF episodes in Parkinson's disease. Using the ARCUS inhaler platform, levodopa is inhaled into the lung where it is delivered to the blood, avoiding the gastrointestinal tract and producing more rapid effects than orally administered levodopa. CVT-301 will be taken as needed, similar to a rescue inhler, which is common in the asthma market. It will not replace the patient's current oral doses of levodopa or other medications, but will be taken in addition to them. Scope
Reasons to buy
For more information visit http://www.researchandmarkets.com/research/vltc4s/cvt301
|